KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Edwards Lifesciences (EW) Long-Term Debt Repayments (2016 - 2022)

Edwards Lifesciences has reported Long-Term Debt Repayments over the past 12 years, most recently at $100000.0 for Q4 2022.

  • For Q4 2022, Long-Term Debt Repayments changed 0.0% year-over-year to $100000.0; the TTM value through Dec 2022 reached $200000.0, down 97.14%, while the annual FY2023 figure was $300000.0, 50.0% up from the prior year.
  • Long-Term Debt Repayments for Q4 2022 was $100000.0 at Edwards Lifesciences, roughly flat from $100000.0 in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $601.2 million in Q4 2018 and troughed at -$8.7 million in Q3 2021.
  • A 5-year average of $65.5 million and a median of $3.8 million in 2019 define the central range for Long-Term Debt Repayments.
  • Biggest five-year swings in Long-Term Debt Repayments: surged 10635.71% in 2018 and later tumbled 495.45% in 2021.
  • Year by year, Long-Term Debt Repayments stood at $601.2 million in 2018, then plummeted by 99.14% to $5.2 million in 2019, then tumbled by 42.31% to $3.0 million in 2020, then tumbled by 96.67% to $100000.0 in 2021, then changed by 0.0% to $100000.0 in 2022.
  • Business Quant data shows Long-Term Debt Repayments for EW at $100000.0 in Q4 2022, $100000.0 in Q2 2022, and $100000.0 in Q4 2021.